More stories

  • in

    Biogen tops estimates, raises profit guidance as Alzheimer’s drug Leqembi gains traction

    Biogen reported third-quarter revenue and adjusted earnings that topped expectations.
    The company also raised its full-year profit guidance.
    Sales of its breakthrough Alzheimer’s drug, Leqembi, along with new rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company’s multiple sclerosis products. 

    A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021.
    Dado Ruvic | Reuters

    Biogen on Wednesday reported third-quarter revenue and adjusted earnings that topped expectations while raising its full-year profit guidance, as sales of its breakthrough Alzheimer’s drug, Leqembi, and other new products gain traction. 
    Biogen now expects full-year adjusted earnings to come in between $16.10 and $16.60 per share, up from a previous forecast of $15.75 to $16.25 per share. The biotech company still anticipates 2024 sales to decline by a low-single-digit percentage. 

    Leqembi, which Biogen shares with the Japanese drugmaker Eisai, became the second drug proven to slow the progression of Alzheimer’s to win approval in the U.S. last summer. The therapy’s launch has been gradual due to bottlenecks related to diagnostic test requirements, regular brain scans and finding neurologists, among other issues. 

    More CNBC health coverage

    Still, uptake of Leqembi has been increasing over the last few quarters. The treatment brought in $67 million in sales for the third quarter, including $39 million from the U.S. 
    Wall Street analysts had expected global sales of $50 million for Leqembi, according to estimates compiled by StreetAccount. The drug posted just $10 million in sales last year following its launch. 
    It is unclear how many patients are currently taking the drug. Leqembi, along with Biogen’s new rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company’s multiple sclerosis products. 
    Here’s what Biogen reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

    Earnings per share: $4.08 adjusted vs. $3.79 expected
    Revenue: $2.47 billion vs. $2.43 billion expected

    Biogen booked sales of $2.47 billion for the quarter, which is down around 3% from the year-earlier period. 
    The drugmaker posted net income of $388.5 million, or $2.66 per share, for the period ended Sept. 30. That compares with a net loss of $68.1 million, or 47 cents per share, for the same period a year ago. 
    Adjusting for one-time items, including certain restructuring charges and costs associated with intangible assets, the company reported earnings of $4.08 per share.

    Don’t miss these insights from CNBC PRO More

  • in

    Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance

    Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.
    The drugmaker also slashed its full-year adjusted profit guidance to a range of $13.02 to $13.52 per share.
    Skyrocketing demand for injectable weight loss and diabetes drugs has forced both Eli Lilly and its main rival, Novo Nordisk, to invest billions to increase manufacturing capacity.

    Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023.
    Mike Blake | Reuters

    Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, and slashed its full-year adjusted profit guidance.
    The company’s stock tumbled 10% in premarket trading. Shares of its main rival, Novo Nordisk, fell roughly 3%.

    Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16.60 per share. The drugmaker cited a $2.8 billion charge recorded during the third quarter and related to its acquisition of bowel disease drugmaker Morphic Holding as denting its results.
    Eli Lilly also lowered the high-end of its revenue outlook for the year and now expects sales of between $45.4 billion and $46 billion. The company’s previous guidance called for revenue of as much as $46.6 billion.
    Here’s what Eli Lilly reported for the period ended September 30 compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

    Earnings per share: $1.18 adjusted vs. $1.47 expected
    Revenue: $11.44 billion vs. $12.11 billion expected

    The September period was Zepbound’s third full quarter on the U.S. market after winning approval from regulators nearly a year ago. The weekly injection raked in $1.26 billion in sales for the period, below the $1.76 billion that analysts expected, according to StreetAccount.
    Meanwhile, Mounjaro posted $3.11 billion in revenue for the third quarter, more than double what it booked in the same period a year ago. But analysts expected $3.77 billion in sales for the diabetes treatment, according to StreetAccount.

    Demand in the U.S. has far outpaced supply for Lilly’s incretin drugs, such as Zepbound and Mounjaro, over the last year. Both treatments mimic certain gut hormones to tamp down a person’s appetite and regulate their blood sugar.
    The popularity of those injectable drugs has forced both Eli Lilly and Novo Nordisk to invest billions to increase manufacturing capacity for the treatments.
    Eli Lilly’s supply woes began to ease earlier this year. As of Wednesday, the Food and Drug Administration’s drug database said all doses of Zepbound and Mounjaro are available in the U.S. after extended shortages. Still, the agency warns that patients may not always be able to immediately fill their prescription for those drugs at a particular pharmacy.

    In an interview with CNBC, Eli Lilly CEO David Ricks said the third-quarter performance of Zepbound and Mounjaro “is not a function of supply.” The company said third-quarter sales of the drugs were negatively impacted by inventory decreases among wholesalers.
    Ricks also said the company pushed back plans to advertise and promote Zepbound due to customer service levels. The drugmaker will begin those efforts in November, he said.
    “When people go and they can’t get their medicine, they’re very frustrated. They tell us that. So we didn’t want to send more people to do that necessarily,” Ricks said.
    Eli Lilly has said it expects incretin drug production in the second half of 2024 to be 50% higher than it was during the same period last year. And Ricks said Wednesday the company expects “even greater” expansions in manufacturing capacity at the end of the year and 2025.
    For the third quarter, Ely Lilly recorded net income of $970.3 million, or $1.07 per share, compared with a net loss of $57.4 million, or 6 cents per share, during the third quarter of 2023.
    Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $1.18 per share for the most recent quarter.
    Revenue was up 20% year over year to $11.44 billion.
    The FDA’s decision to remove tirzepatide, the active ingredient in Zepbound and Mounjaro, from its shortage list has drawn fierce opposition from compounding pharmacies that make customized and sometimes cheaper alternatives to Eli Lilly’s branded drugs. Compounding pharmacies are calling for the FDA to reconsider its decision, as both Eli Lilly and Novo Nordisk attempt to crack down on unapproved versions of their top-selling drugs.
    Ricks told CNBC the company agrees with the FDA that Zepbound and Mounjaro are no longer in shortage, adding, “We have stock.” He added that compounded versions of Eli Lilly’s branded drugs are not regulated by the FDA, raising questions about their safety and efficacy. 
    This story is developing. Please check back for updates. More

  • in

    Chipotle misses revenue estimates as same-store sales growth disappoints

    Chipotle Mexican Grill on Tuesday reported mixed quarterly results as earnings beat expectations but revenue fell short.
    The burrito chain’s same-store sales rose 6%, just shy of StreetAccount estimates of 6.3%.
    For the full year, Chipotle reiterated its outlook that same-store sales will grow by a mid- to high-single-digit percentage.

    A customer holds a bag of food outside of a Chipotle restaurant in New York on Jan. 12, 2024.
    Angus Mordant | Bloomberg | Getty Images

    Chipotle Mexican Grill on Tuesday reported mixed quarterly results despite another quarter of higher traffic to its restaurants. 
    Shares of the company fell 3% in extended trading.

    Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

    Earnings per share: 27 cents adjusted vs. 25 cents expected
    Revenue: $2.79 billion vs. $2.82 billion expected

    Chipotle reported third-quarter net income of $378.4 million, or 28 cents per share, up from $313.2 million, or 23 cents per share, a year earlier. 
    The company’s food and beverage costs increased during the quarter, in part due to Chipotle’s decision to reemphasize generous portions after social media-fueled backlash over the size of its burrito bowls this summer.
    Excluding items, the company earned 27 cents per share.
    Net sales climbed 13% to $2.79 billion. 

    Same-store sales rose 6%, just shy of StreetAccount estimates of 6.3%. Traffic to restaurants increased 3.3% in the quarter, continuing the chain’s streak of bucking an overall slump in foot traffic across the industry. While many consumers have opted to eat out less, Chipotle has benefited from having a wealthier customer base that is willing to pay more for its burritos and bowls. 
    “We’re seeing growth from all income cohorts at present,” interim CEO Scott Boatwright said on CNBC’s “Closing Bell: Overtime” on Tuesday.
    While demand was weaker at the start of the third quarter, Boatwright said sales accelerated throughout the period, particularly as Chipotle reintroduced its smoked brisket. The limited-time menu item is currently the most expensive protein, topping even the chain’s steak and beef barbacoa options.
    Boatwright, formerly Chipotle’s chief operating officer, stepped in to lead the company after former CEO Brian Niccol departed in late August to pilot Starbucks’ turnaround. On the company’s conference call on Tuesday, Boatwright reassured investors that the chain’s strategy is not changing despite the leadership shake-up.
    “I have worked alongside our talented executive team to craft and evolve our successful strategy, and we will continue to execute against it,” he said.
    Digital sales accounted for 34% of the chain’s quarterly food and beverage revenue.
    The company opened 86 new locations during the quarter, 73 of which included a “Chipotlane” dedicated to online order pickup.
    Chipotle is also investing in new equipment to improve its preparation and cooking. The company plans to roll out new produce slicers to all restaurants by next summer. Chipotle has also added dual-sided grills to 74 restaurants and will announce early next year its strategy to add the equipment to new and existing restaurants.
    For the full year, Chipotle reiterated its outlook that same-store sales will grow by a mid- to high-single-digit percentage. The company also anticipates it will open between 285 and 315 new restaurants this year.
    Looking to 2025, Chipotle plans to open between 315 and 345 new locations. More than 80% of those restaurants will include a Chipotlane.

    Don’t miss these insights from CNBC PRO More

  • in

    Too many people want to be social-media influencers

    Influencers are everywhere you look these days—including on America’s campaign trail. Some 200 social-media stars attended the Democratic National Convention in August, where they were entertained at lavish parties and on boat trips. A few even got to chat with Kamala Harris. Donald Trump has likewise given interviews to influencer bros such as Logan Paul and Theo Von in an effort to appeal to their followers. More

  • in

    McDonald’s executives say E. coli outbreak is ‘behind us’

    McDonald’s CEO Chris Kempczinski told investors that the company views the E. coli outbreak linked to its Quarter Pounder burgers as “being behind us.”
    The outbreak isn’t expected to have a material impact on the company’s business, CFO Ian Borden said.
    McDonald’s is bringing Quarter Pounder burgers — sans slivered onions — back to the roughly 900 restaurants affected by the outbreak.

    McDonald’s Chris Kempczinski speaks about fresh beef expansion at a McDonald’s event in Oak Brook, Illinois.
    Richa Naidu | Reuters

    A week after health authorities publicly linked a deadly E. coli outbreak to McDonald’s Quarter Pounder burgers, the company’s CEO, Chris Kempczinski, told investors that the situation is now behind them.
    “How we’ve handled the issue, now that we’re moving … we view it as being behind us,” Kempczinski said on the company’s call Tuesday.

    During his prepared remarks, he said that the “situation appears to be contained.”
    On Sunday, McDonald’s said Quarter Pounder burgers would return to roughly a fifth of its U.S. footprint where the company had pulled the menu item following the outbreak. That amounts to roughly 3,000 restaurants, the company told CNBC Tuesday.
    Health authorities didn’t detect any E. coli in the burger’s fresh beef patties, but the Food and Drug Administration is still investigating the slivered onions that are used in Quarter Pounders as the likely source. McDonald’s has stopped sourcing onions from the supplier indefinitely, and around 900 locations will serve the Quarter Pounder sans slivered onions.
    McDonald’s saw daily sales and traffic to its U.S. restaurants turn negative in the days immediately following the outbreak announcement as consumers reacted to the news, CFO Ian Borden said. He added that the company isn’t anticipating a material impact to the business.
    Now McDonald’s is focused on reassuring diners and returning to the higher sales it had been seeing earlier in October, fueled by its $5 value meal and the launch of the Chicken Big Mac.

    “What I would say is we certainly believe the most significant events are behind us, and the work to do right now is focused on restoring consumer confidence, getting our U.S. business back to that strong momentum that I just talked about,” Borden said.
    On Tuesday, McDonald’s reported U.S. third-quarter same-store sales that increased 0.3% over the prior-year period, reversing a decline during the second quarter but slightly weaker than the 0.5% growth projected by StreetAccount estimates.
    McDonald’s beat Wall Street’s estimates for its quarterly earnings and revenue, but its overall same-store sales fell 1.5%, fueled by weaker demand in key international markets.
    Shares of McDonald’s fell as much as 2.5% in premarket trading on Tuesday but recovered during the conference call. The stock was roughly flat when the markets opened.
    Earlier on the call, Kempczinski apologized to customers for the situation.
    “The recent spate of E. coli cases is deeply concerning, and hearing reports of how this has impacted our customers has been wrenching for us,” Kempczinski said. “On behalf of the entire system, we are sorry for what our customers have experienced. We offer our sincere and deepest sympathies, and we are committed to making this right.”
    As of Friday, 75 health cases across 13 states have been tied to the outbreak, including one death of an older adult.
    At least three lawsuits have already been filed against McDonald’s by victims of the outbreak.
    Clarification: This story has been updated to clarify that McDonald’s is returning the Quarter Pounder to roughly 3,000 locations after pulling the menu item following an E. coli outbreak. About 900 restaurants will serve the burgers without slivered onions.

    Don’t miss these insights from CNBC PRO More

  • in

    Harris vs. Trump: Auto insiders weigh in on both candidates, top issues

    Michigan and its automotive industry remain critical to the presidential election, as Vice President Kamala Harris and former President Donald Trump campaign in the state.
    Auto executives and lobbyists told CNBC that they’re preparing for all outcomes in the election — and electric vehicles, trade, tariffs, China, emissions regulations and labor are their top issues.
    Officials expect a Harris victory to be a continuation, but not a copy, of the past four years under President Joe Biden, while they think Trump would likely return to policies and actions from his first presidential term.

    New Ford F-150 trucks go through the assembly line at the Ford Dearborn Plant on April 11, 2024 in Dearborn, Michigan. 
    Bill Pugliano | Getty Images

    DETROIT — The automotive industry has become a crucial topic during the 2024 presidential election as Michigan — home of the Motor City and 1.1 million automotive jobs — remains a critical swing state.
    Vice President Kamala Harris, former President Donald Trump, and their running mates and supporters have made Michigan a second home in recent weeks as the campaigns attempt to win over undecided voters in the Great Lakes State.

    Since 2008, whichever candidate has won the state has moved into the White House, including Trump in 2016 and President Joe Biden in 2020.
    “Michigan’s 16 electoral votes have helped thrust Autos into the debate. Between Trump’s hyperactive and contradictory statements and Harris’ quieter views lay deep differences but also convergence,” Jefferies analyst Philippe Houchois wrote in an investor note Monday.
    While major automakers and suppliers have shied away from publicly endorsing either presidential candidate, executives and lobbyists from several companies spoke to CNBC on the condition of anonymity to discuss how they’re preparing for each candidate, as well as a likely divided Congress.
    Electric vehicles, trade, tariffs, China, emissions regulations and labor are among the top issues automakers are monitoring, according to industry executives and policy experts.

    Harris vs. Trump

    Officials expect a Harris victory to be a continuation, but not a copy, of the past four years under Biden. They think she would potentially be more understanding of businesses, but there are concerns.

    Some of her policies and potential appointments are unclear, experts said, and her alignment with the United Auto Workers, particularly union President Shawn Fain who has been a combative foe to automakers, is concerning to some.

    US Vice President and Democratic presidential nominee Kamala Harris greets union workers as she tours an International Union of Painters and Allied Trades training facility in Macomb, Michigan, on October 28, 2024. 
    Drew Angerer | AFP | Getty Images

    If Trump wins reelection, automotive industry officials largely expect that he’ll return to policies and actions from his first presidential term, but those stances could be potentially more aggressive than they were before.
    If he’s in office, insiders expect he would roll back or eliminate tightening federal emissions and fuel economy like he did during his first term; renew a battle between California and other states that set their own standards; and potentially enact funding changes to the Biden administration’s key Inflation Reduction Act of 2022 legislation.
    Officials said it would be difficult for Trump to completely gut the IRA, but he could defund or limit EV subsidies through executive orders or other policy actions.
    Automakers, suppliers and other auto-related companies are preparing for both outcomes as well as a split in Congress, insiders said.

    Republican presidential nominee and former U.S. President Donald Trump speaks as he visits a campaign office in Hamtramck, Michigan, U.S. October 18, 2024. 
    Brian Snyder | Reuters

    “There’s no perfect scenario. Both candidates offer some opportunities and challenges,” said a leading lobbyist and public policy expert for a major automaker. “Everyone in our business has to look at the gamut of scenarios.”
    Some Wall Street analysts speculate legacy automakers — specifically the “Detroit” companies General Motors, Ford Motor and Chrysler parent Stellantis — would benefit most with Trump and Republican control of Congress.
    EV startups such as Rivian Automotive and Lucid Group would benefit more with a Democratic win, largely due to expected plans involving EVs and fuel economy requirements. That’s despite Tesla CEO Elon Musk’s continued support for Trump.

    Emissions regulations

    The most imminent issues for automakers are fuel economy and emissions regulations, specifically regarding 2026 model year regulations for California and several states that follow them such as Washington, Oregon and New York.
    Current requirements under the “Advanced Clean Cars II” regulations of 2022 call for 35% of 2026 model year vehicles, which will begin to be introduced next year, to be zero-emission vehicles. Battery-electric, fuel cell and, to an extent, plug-in hybrid electric vehicles qualify as zero emission.
    The California Air Resources Board reports 12 states and Washington, D.C., have adopted the rules; however, roughly half have them starting for the 2027 model year. They are part of CARB’s Advanced Clean Cars regulations that include mandating 100% of new vehicle sales be zero-emission models by 2035.

    Only 11 states and the District of Columbia had an EV market share above 10% to begin this year, according to the Alliance for Automotive Innovation, a trade association and lobby group that represents most major automakers operating in the U.S.
    Officials said regardless of who wins the White House, many automakers will push for the CARB mandates to be postponed. They also would expect Trump to roll back or freeze the Corporate Average Fuel Economy, or CAFE, standards for model years 2027-2031.
    Several automotive insiders said they expect Harris would work on a middle ground for such standard with the automakers, much like Biden, to an extent, has done.

    EVs, IRA

    Electric vehicles and the U.S. policies supporting them, such as the Inflation Reduction Act, are top of mind for automotive industry executives and lobbyists. There could be major changes in regulations and incentives for EVs if Trump regains power, which has placed the industry in a temporary limbo.
    “Depending on the election in the U.S., we may have mandates; we may not,” Volkswagen Group of America CEO Pablo Di Si said Sept. 24 during an Automotive News event. “Am I going to make any decisions on future investments right now? Obviously not. We’re waiting to see.”

    Electric vehicles transformed from a popular talking point for Democrats four years ago to a rallying call for Republicans.
    Republicans, led by Trump, have largely condemned EVs, saying that they are being forced upon consumers and that they will ruin the U.S. automotive industry. Trump has vowed to roll back or eliminate many vehicle emissions standards under the Environmental Protection Agency and incentives to promote production and adoption of the vehicles.
    In contrast, Democrats, including Harris, have historically supported EVs and related incentives.
    Harris hasn’t been as vocal about backing EVs lately amid slower-than-expected consumer adoption of the vehicles and consumer pushback. She has said she does not support an EV mandate such as the Zero-Emission Vehicles Act of 2019, which she co-sponsored during her time as a senator, that would have required automakers to sell only electrified vehicles by 2040.
    Lucid Group CEO Peter Rawlinson told CNBC on Monday that regardless of which presidential candidate wins the election, he believes America’s EV industry is still in its infancy and needs to continue to be “nurtured.”
    Rawlinson, whose company has the most efficient EVs on sale, also argues the IRA should favor not just the size of a battery, like it currently does, but the efficiency of the vehicles.
    “That’s effectively incentivizing electron-guzzling EVs,” he said. “It actually incentivized to put more batteries in and be less efficient.”

    Trade/tariffs and China

    Led by fears of China’s automotive industry expanding globally, both Trump and Harris have expressed intentions to review the U.S. North American trade deal, formally known as the United States-Mexico-Canada Agreement.
    The deal, which replaced the North American Free Trade Agreement, or NAFTA, was negotiated under Trump’s first term in office and took effect in 2020. However, the former president and Democrats have said it needs to be improved to better support American automotive production.
    While Trump touted the deal when it was renegotiated, Harris was one of 10 U.S. senators who voted against USMCA at the time.
    GM CEO Mary Barra last week said the automaker is “paying careful attention” to the election, including how potential changes in trade and tariffs could impact the company.
    “We have and we’ll continue to engage constructively with the policymaking process regardless of the election outcome. When you look at the number of jobs created in the U.S., even with some vehicles that are manufactured outside, a lot of them are in our partners from an ally perspective,” she said. “It’s a very complex situation.”
    Tariffs are central to Trump’s plan for the auto industry. He has said he would be willing to increase tariffs dramatically to prevent Chinese automakers from importing cars into the U.S. from factories in Mexico.
    Chinese automakers are not currently doing that, but are expected to attempt to use that method of importing in the years ahead, as they expand sales and build localized production plants in the country.

    Harris has reportedly called Trump’s tariff proposals “a sales tax on the American people.” The vice president hasn’t outlined any specific changes she’d make to the current tariff structure if elected, including on Biden’s announcement of raising the tariff rate on EVs imported from China from 25% to 100%.
    Non-U.S.-based automakers, which together account for 48% of U.S. production and 52% of USMCA production, look more positively leveraged to Harris winning, according to Jefferies.

    Labor

    Of the many issues regarding the automotive industry, officials who spoke to CNBC were nearly unanimous regarding labor: They’re concerned a Harris win would continue to mean increased power for organized labor.
    Biden, followed by Harris, gave the United Auto Workers and Fain — the union’s president — more spotlight than any previous presidents in modern times, including a speech at the Democratic National Convention.
    The UAW arguably has more political clout than any time in a generation, led by Fain and his top advisors who he brought in from outside the union’s ranks. But there has been a divide in the UAW and other unions regarding the historically Democratic-backed organizations and their members.

    While the Teamsters declined to endorse a candidate due to a divide in the union, UAW leaders not only endorsed Harris but have been a driving force for her election campaign in Michigan and other states.
    The UAW last week said internal polling showed increasingly “strong support for Kamala Harris over Donald Trump, with Harris’ lead over Trump surging in the last month.”
    Meanwhile, Trump and Fain have consistently criticized one another over the past year, as the union attempts to organize as many auto plants as possible following major contract gains won during negotiations last year with the traditional Detroit automakers.
    Blue-collar workers such as UAW members were viewed as crucial supporters for Trump’s first presidential election over Democratic candidate Hillary Clinton in 2016.
    — CNBC’s Michael Bloom contributed to this report.

    Don’t miss these insights from CNBC PRO More

  • in

    Gatorade signs Duke basketball’s Cooper Flagg to NIL deal

    Duke men’s basketball player Cooper Flagg has agreed to a name, image and likeness deal with PepsiCo-owned Gatorade.
    Flagg will likely be the first overall draft pick in next year’s NBA Draft.
    Flagg is one of many players capitalizing on their NIL opportunities in this new era of college sports.

    Cooper Flagg, #2 of the Duke Blue Devils, moves the ball against the Arizona State Sun Devils during the game at Cameron Indoor Stadium in Durham, North Carolina, on Oct. 27, 2024.
    Grant Halverson | Getty Images

    Gatorade is adding another big-name athlete to its already loaded portfolio.
    First-year Duke men’s basketball player Cooper Flagg has agreed to a name, image and likeness deal with PepsiCo-owned Gatorade, according to a Tuesday announcement. Flagg is projected to be the first overall draft pick in the 2025 National Basketball Association Draft and already has NIL deals with brands including New Balance and New Era.

    “This has been a big year for me on and off the court, and Gatorade has been there the whole way,” Flagg said in a news release. “From being named the Gatorade Best Male Player of the Year to now officially joining the team, it’s been surreal to have my name mentioned with some of the biggest names in basketball. The Gatorade roster is iconic, and I’m excited to work with them as I take this next step.”  
    As part of the deal, Gatorade will use Flagg in its marketing. Terms of the deal, like Flagg’s others, are undisclosed.
    Flagg is the latest example of what is already a dramatically different college sports landscape than what existed prior to 2021. Since the approval of NIL deals, college athletes have been able to capitalize on endorsement deals in ways they never could before.
    Players like Flagg, a highly touted prospect and likely NBA star, have been able to net NIL deals, some of them reportedly worth millions of dollars.
    Flagg is Gatorade’s first men’s college basketball athlete, joining women’s college basketball stars such as University of Connecticut’s Paige Bueckers and University of Southern California’s JuJu Watkins as well as collegiate football stars such as Colorado’s Shedeur Sanders.

    “Cooper is an incredible talent who quickly emerged as one of the best young athletes in the nation, and we know he has a bright future ahead of him,” said Jeff Kearney, global head of sports marketing at Gatorade, in a statement. “At Gatorade, we work with the best of the best, so we’re proud to welcome Cooper to the family and are excited to be fueling him as his collegiate career begins.”
    Flagg has inked his NIL deals all before playing in a college basketball game that counts toward a season record. Duke plays its first regular-season game Monday against Maine.

    Don’t miss these insights from CNBC PRO More

  • in

    Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales

    Pfizer reported third-quarter revenue and adjusted profit that blew past expectations.
    The company hiked its full-year outlook as its Covid vaccine and antiviral pill Paxlovid helped boost sales.
    It is a critical quarterly report for Pfizer, which is grappling with activist pressure from Starboard Value.

    The PAXLOVID antiviral medications nirmatrelvir co-packaged with ritonavir were developed by Pfizer to treat the virus.
    Patrick T. Fallon | Afp | Getty Images

    Pfizer on Tuesday reported third-quarter revenue and adjusted profit that blew past expectations as the company’s Covid vaccine and antiviral pill Paxlovid helped boost sales.
    The pharmaceutical giant also hiked its full-year outlook and now expects to book adjusted earnings per share of $2.75 to $2.95, up from its previous guidance of 2.45 to $2.65 per share. 

    Pfizer now expects revenue in a range of $61 billion to $64 billion, up from a previous revenue forecast of between $59.5 billion and $62.5 billion. That includes roughly $5 billion in expected revenue from its Covid vaccine and $5.5 billion from Paxlovid.
    Here’s what the company reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

    Earnings per share: $1.06 adjusted vs. 62 cents expected
    Revenue: $17.7 billion vs. $14.95 billion expected

    The company booked third-quarter net income of $4.47 billion, or 78 cents per share. That compares with net loss of $2.38 billion, or 42 cents per share, during the same period a year ago. Excluding certain items, including restructuring charges and costs associated with intangible assets, the company posted earnings per share of $1.06 for the quarter.
    Pfizer reported revenue of $17.7 billion for the third quarter, up 31% from the same period a year ago.
    It is a critical quarterly report for Pfizer, which is cutting costs as it works to recover from the rapid decline of its Covid business and share price over the last two years. The drugmaker’s shares are trading at about half of their pandemic-era high, putting the company’s market cap at roughly $163 billion. 

    Pfizer is also grappling with activist pressure from Starboard Value, which has a roughly $1 billion stake in the pharmaceutical company. 
    Starboard managing member Jeff Smith contends that Pfizer failed to capitalize on the windfall earned from its Covid products and, in the process, destroyed tens of billions of dollars in market value. Smith points to what he believes are management’s poor investments in research and development and hefty acquisitions that have yet to be fruitful for the struggling company. 
    Notably during the quarter, Pfizer withdrew from world markets a critical sickle cell drug it had acquired in a $5.4 billion deal for Global Blood Therapeutics. 
    Starboard is calling for a massive overhaul at Pfizer, saying that the company needs to be more disciplined on its investments.
    Meanwhile, Pfizer reiterated Tuesday it is on track to deliver at least $4 billion in savings by the end of the year. The company in May announced a multiyear plan to slash costs, with the first phase of the effort slated to deliver $1.5 billion in savings by 2027. 
    Paxlovid brought in $2.7 billion in sales for the quarter, up from the $202 million it posted in the year-earlier period. 
    That growth is mainly due to strong demand, particularly in the U.S. during a recent wave of the virus. It was also helped by a one-time contractual delivery of 1 million treatment courses of Paxlovid to the federal government’s national stockpile during the third quarter, which accounted for $442 million in revenue. 
    Those results are higher than the $707.7 million in sales that analysts were expecting for Paxlovid, according to estimates compiled by StreetAccount.
    The company’s Covid shot booked $1.42 billion in revenue, up 9% from the same period a year ago.
    Pfizer said that growth was mainly driven by the timing of stocking for the vaccine, pointing to the earlier approval of the updated version of the shot this fall compared with last year. That growth was partially offset by lower contractual deliveries and demand in international markets.
    Analysts expected $1.04 billion in sales for the shot, according to StreetAccount.

    Non-Covid product growth

    Excluding Covid products, Pfizer said revenue for the third quarter rose 14% on an operational basis, fueled by approved cancer products from Seagen, which it acquired last year for a whopping $43 billion.
    Those drugs brought in $854 million in revenue for the quarter, including $409 million from a targeted treatment for bladder cancer called Padcev as well as $268 million from Adectris, a drug that targets certain lymphomas. Pfizer completed its acquisition of Seagen in December.
    Revenue also got a boost from sales of Pfizer’s Vyndaqel drugs, which are used to treat a certain type of cardiomyopathy, a disease of the heart muscle. Those drugs booked $1.45 billion in sales, up 62% from the third quarter of 2023.
    Analysts had expected that group of drugs to rake in $1.37 billion for the quarter, according to estimates from StreetAccount.  
    Pfizer said its blood thinner Eliquis, which is co-marketed by Bristol Myers Squibb, also helped drive revenue growth during the period. The drug posted $1.62 billion in revenue for the quarter, up 8% from the year-earlier period. 
    That is slightly higher than the $1.59 billion that analysts were expecting, according to StreetAccount. 
    Sales of Eliquis could take a hit in 2026, however, when a new price for the drug goes into effect for certain Medicare patients following negotiations with the federal government. Those price negotiations are a key provision of President Joe Biden’s Inflation Reduction Act that the pharmaceutical industry fiercely opposes.
    Meanwhile, Pfizer’s vaccine against respiratory syncytial virus, or RSV, saw $356 million in revenue for the third quarter. The shot, known as Abrysvo, entered the market during the third quarter of 2023 for seniors and expectant mothers who can pass on protection to their fetuses.
    Analysts had expected the shot to generate sales of $255.4 million, according to StreetAccount estimates.
    Last week, Pfizer’s RSV shot won approval for adults ages 18 to 59 who are at increased risk for the disease – a decision that will likely significantly expand the reach of the jab in the U.S.

    Don’t miss these insights from CNBC PRO More